---
schema_version: "secwatch.filing_event.v1"
accession: "0001826667-25-000011"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2025-01-31T23:59:59+00:00"
generated_at: "2026-05-27T04:48:13.943874+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# TriSalus Life Sciences appoints two new directors, expands board to 11

## Summary
- William Valle (Class I, term to 2027) and Gary Gordon (Class III, term to 2026) appointed Jan 29, 2025.
- Valle receives $50k cash retainer plus $7.5k each for Audit and Compensation committees; initial option grant of 35k shares (3-yr vest).
- Gordon receives $50k cash retainer plus $7.5k for Science & Technology Committee; same option grant structure as Valle.
- No arrangements or understandings existed for selection of Valle or Gordon; no reportable transactions under Item 404(a).

## SEC filing metadata
- accession: 0001826667-25-000011
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2025-01-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000011/0001826667-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000011/tlsi-20250129.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001826667-25-000011
- JSON: https://secwatch.observer/filing/0001826667-25-000011.json
- Plain text: https://secwatch.observer/filing/0001826667-25-000011.txt

## Key facts
- Executive change
  Gary Gordon was appointed as Director at TriSalus Life Sciences, Inc..
  - Action: appointed
  - Role: Director
  source text: On January 29, 2025, the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) increased the size of the Board to 11 directors and appointed William Valle as a Class I director of the Company and Gary Gordon as Class III director of the Company, with their term of office expiring at the 2027 and 2026 annual meeting of stockholders, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000011/0001826667-25-000011-index.htm
- Executive change
  William Valle was appointed as Director at TriSalus Life Sciences, Inc..
  - Action: appointed
  - Role: Director
  source text: On January 29, 2025, the Board of Directors (the “Board”) of TriSalus Life Sciences, Inc. (the “Company”) increased the size of the Board to 11 directors and appointed William Valle as a Class I director of the Company and Gary Gordon as Class III director of the Company, with their term of office expiring at the 2027 and 2026 annual meeting of stockholders, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000182666725000011/0001826667-25-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.